Autologous hematopoietic transplantation following COVID-19 infection

Autologous hematopoietic cell transplantation following induction therapy is standard of care for most patients with newly diagnosed multiple myeloma (N Engl J Med 2017, 376; 1311). Though active COVID-19 infection is typically a contraindication to aggressive therapy, little is known about the safety of autologous transplantation after resolution of acute symptoms and undetectable pathogen by nasopharyngeal PCR.

Automated summary

Autologous hematopoietic cell transplantation is a standard of care for most patients with newly diagnosed multiple myeloma, but the safety of undergoing this procedure after COVID-19 infection is not well understood.